Fig. 5.
![Fig. 5. Treatment of the BCL1 lymphoma with RIT late in the disease. Groups of 10 mice were given 106 cells on day 0 as usual and then left until day 14 before treating IV with radioiodinated MoAb (750 μg/animal [approximately 7.5 MBq]). The treatments included: Control IgG (⋆); control IgG2a (⧫); anti-Id (□, ▪); anti-MHC II (TI2-3; ○, •); and anti-MHCII (N22; ▿, ▾). The solid and open symbols represent MoAb labeled with and without radioactive iodine, respectively. Surprisingly the131I–anti-Id MoAb provided long-term protection to all the mice.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/94/1/10.1182_blood.v94.1.233.413a25_233_243/6/blod41325005x.jpeg?Expires=1724233375&Signature=IDjImVy6co1gfq7vErfMii0LEk95afQwQm2XAhPF4OX90pe3jYv0QEh-i5x0dWBbiomrA80iVWGCO1otB7TM9B-4XXtrlbvkHjbKrLngKSp1IrVE2z1U3SCwEkPop7pEU9ARFtVjeacLiVQdTNkVjt0Mjg2nNGHRuszfRXmBjq~3XvxNGIlgKOo8eYcTDJ~M0sqn03v-RMrNmoLzDg9KWE0qHfbF7AL2yTc-lgmpHqnxp4JvQ92nY9P-ZQe97OJ5n-Xro9bUAVoP3LAr5yofFIXk~3k2jZNVT9xGGXxyC8shgiEJcQkxcrI62lxgv1-ChoRA6oSkcuoRTSB9bAIv0g__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Treatment of the BCL1 lymphoma with RIT late in the disease. Groups of 10 mice were given 106 cells on day 0 as usual and then left until day 14 before treating IV with radioiodinated MoAb (750 μg/animal [approximately 7.5 MBq]). The treatments included: Control IgG (⋆); control IgG2a (⧫); anti-Id (□, ▪); anti-MHC II (TI2-3; ○, •); and anti-MHCII (N22; ▿, ▾). The solid and open symbols represent MoAb labeled with and without radioactive iodine, respectively. Surprisingly the131I–anti-Id MoAb provided long-term protection to all the mice.
